Breast Cancer

Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Breast Cancer

The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF...

CNS Cancers

Dinutuximab vs Temsirolimus in Combination Therapy for Children With Resistant Neuroblastoma

A randomized phase II trial (Children’s Oncology Group [COG] ANBL1221) has resulted in the selection of dinutuximab plus irinotecan/temozolomide...

Colorectal Cancer

First-Line Cetuximab vs Bevacizumab Plus Chemotherapy in KRAS Wild-Type Colorectal Cancer

A phase III trial has shown no significant difference in overall survival with first-line cetuximab vs bevacizumab plus chemotherapy...


Advertisement

More Top Stories

Clifford A. Hudis, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s CEO

Get to Know Your ASCO President-Elect: Monica M. Bertagnolli, MD, FASCO

Monica M. Bertagnolli, MD, FASCO, a long-time member and volunteer, began her term as ASCO President-Elect in June 2017; she will serve as 2018–2019 ASCO President. An active ASCO member since 1995, Dr. Bertagnolli is Chief of the Division of Surgical Oncology at Dana-Farber/Brigham and Women’s...

Advertisement

Tibetan Yoga Practice May Improve Sleep Quality for Patients With Breast Cancer Undergoing Chemotherapy

Participating in twice-weekly practice of Tibetan yoga may reduce sleep disturbances and improve sleep quality in breast cancer patients receiving chemotherapy, according to a study published by Chaoul et al in Cancer. The study, led by researchers from The University of Texas MD Anderson Cancer...

Bladder Cancer

David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045

Issues in Oncology
Health-Care Policy
Global Cancer Care
Cost of Care

For the Impoverished, Health Care Is a Luxury

Cancer is the second leading cause of death worldwide, and the global burden is on an inexorably upward trajectory. For the year 2012, there were 14.1 million new cancer cases and 8.2 million cancer-related deaths worldwide.1 It is predicted that by the year 2035, there will be 23.9 million new...

Hematologic Malignancies

Recent FDA Actions Include New Formulation, Expanded Indications for Oncology-Hematology Drug Products

The U.S. Food and Drug Administration (FDA) recently granted approval to olaparib tablets (Lynparza) as a maintenance therapy for ovarian cancer and to inotuzumab ozogamicin (Besponsa), for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)....

Positive Results from Phase III MURANO Trial Evaluating Venetoclax in Combination With Rituximab in Relapsed/Refractory CLL

The phase III MURANO study of venetoclax (Venclexta) tablets in combination with rituximab (Rituxan) met its primary endpoint. Results showed that the combination prolonged progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with bendamustine...

Gynecologic Cancers

Sandro Pignata, MD, PhD, on Ovarian and Related Gynecologic Cancers: Expert Perspective on Three Key Trials

NCCN Foundation Announces Fifth 2017 Young Investigator Award

THE NCCN Foundation has granted its fifth Young Investigator Award for the 2017 cycle to Liqin Zhu, PhD, of St. Jude Children’s Research Hospital/ University of Tennessee Health Science Center, for the study titled, “Patient-Derived Tumor Spheroids for High-Risk Hepatoblastoma Drug Discovery.”...

Advertisement

Overall Survival With Nivolumab/Ipilimumab, or Nivolumab Alone, vs Ipilimumab in Advanced Melanoma

Overall survival outcomes in the phase III CheckMate 067 trial indicate improved survival with nivolumab (Opdivo)/ipilimumab (Yervoy) vs ipilimumab and with nivolumab vs ipilimumab in patients with previously untreated advanced melanoma. These findings were reported in The New England Journal of...